Barclays Maintains Overweight on Stryker, Lowers Price Target to $394

Benzinga Newsdesk www.benzinga.com Negative 90.3%

Neg 90.3% Neu 0% Pos 0%

Barclays analyst Matt Miksic maintains Stryker (NYSE:SYK) with a Overweight and lowers the price target from $469 to $394.